Monday, November 13, 2006


Canaccord Adams upgrades HANS to Buy from Hold and raises their tgt to $37 from $33 and adds the stock to their Best Ideas list saying they now have high confidence that revenue/earnings expectations can be met and that future analyst estimate revisions will be positive rather than negative.

CIBC upgrades CEPH to Outperform from Sector Perform with an $89 tgt saying they believe strong sales of Fentora and Provigil will help offset sales lost to generic Actiq. They believe 4Q and '07 top-line results that beat expectations and raised co guidance will drive near-term upside.

ISIS Pharma reports ISIS 301012 significantly reduces all atherogenic lipids when dosed as a single agent and when coadministered with satins (10.38 ) : Co announces new results from two Phase 2 clinical trials of ISIS 301012 presented at the American Heart Association Annual Scientific Sessions. In the first study reported, patients with high cholesterol on stable doses of statins were treated with ISIS 301012 for five weeks. Patients who received 300 mg/week of ISIS 301012 in this study achieved a 51% reduction in LDL-cholesterol, a 42% reduction in total cholesterol, and a 41% reduction in triglycerides beyond the levels achieved with statins alone. Isis also presented new results from an ongoing study in which patients with high cholesterol were treated for three months with 300 mg/week of ISIS 301012 as a single agent. Data from this study for dose cohorts through 200 mg/week were previously reported. In this study, increasing the dose of ISIS 301012 to 300 mg/week further reduced atherogenic lipids, with improvements in LDL-C, TC and TG of 62%, 46% and 43%, respectively.

Courtesy of

My note: ISIS gapping up to $14.00 in pre-market on high volume. ISIS has not seen these prices in years but looking at the monthly timeframe, there is resistance in the $15.00 area.

No comments: